We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HALO Stock Rises 36% in a Month: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
Halozyme's shares surged 36.4% in a month after strong results and higher 2026 revenue guidance.
Investor optimism in HALO's ENHANZE is rising as strong results and higher royalty growth boost sentiment.
Higher ENHANZE-driven royalties from J&J and argenx boosted HALO's first-half 2026 revenues.
Shares of Halozyme Therapeutics (HALO - Free Report) have risen 36.4% in the past month, primarily driven by growing investor confidence in its novel drug-delivery technology, ENHANZE, which enables the subcutaneous (“SC”) administration of drugs. Earlier this month, the company reported robust second-quarter 2026 results and raised its full-year 2026 financial outlook, further boosting investor sentiment and contributing to the recent share-price gain.
Halozyme has collaboration agreements with large pharma companies, which use its ENHANZE technology for the development of SC formulations of their various approved drugs.
Per the agreements, these companies have been granted worldwide license rights to develop and commercialize their products using ENHANZE technology. These deals generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Halozyme has several marketed partnered drugs based on the ENHANZE technology, including the SC formulation of J&J’s (JNJ - Free Report) Darzalex, argenx’s (ARGX - Free Report) Vyvgart Hytrulo and Roche’s Phesgo.
Year to date, shares of Halozyme have rallied 57.7% compared with the industry’s rise of 13.8%.
Image Source: Zacks Investment Research
Halozyme Banks on Higher Royalties
Halozyme’s top line currently comprises product sales, royalty payments, as well as revenues under collaboration agreements related to its ENHANZE technology with some large pharma companies.
The company’s total revenues in the first half of 2026 were primarily driven by higher royalty payments from J&J for SC Darzalex, as well as argenx for Vyvgart Hytrulo.
HALO’s revenues from royalties rose 46.7% year over year to $373.8 million during the first half of 2026.
Halozyme has two commercial proprietary products, Hylenex and Xyosted. Incremental sales from these products also boosted Halozyme’s revenues during the first half of 2026. Total product sales increased 63% year over year to $260.1 million during this period.
Reflecting the strong business performance, Halozyme raised its full-year 2026 financial outlook. The company now expects 2026 revenues of $1.84-$1.91 billion, up from its previous guidance of $1.71-$1.81 billion.
Meanwhile, royalty revenues are now anticipated in the range of $1.22-$1.25 billion compared with the earlier projection of $1.13-$1.17 billion.
Halozyme’s recent business developments and continued growth in royalty revenues from partners are expected to support top-line growth and strengthen its long-term growth outlook. These catalysts could provide further support to the stock’s positive momentum.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 10% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
View the Zacks #1 Rank List
Image: Bigstock
HALO Stock Rises 36% in a Month: Here's What You Should Know
Key Takeaways
Shares of Halozyme Therapeutics (HALO - Free Report) have risen 36.4% in the past month, primarily driven by growing investor confidence in its novel drug-delivery technology, ENHANZE, which enables the subcutaneous (“SC”) administration of drugs. Earlier this month, the company reported robust second-quarter 2026 results and raised its full-year 2026 financial outlook, further boosting investor sentiment and contributing to the recent share-price gain.
Halozyme has collaboration agreements with large pharma companies, which use its ENHANZE technology for the development of SC formulations of their various approved drugs.
Per the agreements, these companies have been granted worldwide license rights to develop and commercialize their products using ENHANZE technology. These deals generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Halozyme has several marketed partnered drugs based on the ENHANZE technology, including the SC formulation of J&J’s (JNJ - Free Report) Darzalex, argenx’s (ARGX - Free Report) Vyvgart Hytrulo and Roche’s Phesgo.
Year to date, shares of Halozyme have rallied 57.7% compared with the industry’s rise of 13.8%.
Image Source: Zacks Investment Research
Halozyme Banks on Higher Royalties
Halozyme’s top line currently comprises product sales, royalty payments, as well as revenues under collaboration agreements related to its ENHANZE technology with some large pharma companies.
The company’s total revenues in the first half of 2026 were primarily driven by higher royalty payments from J&J for SC Darzalex, as well as argenx for Vyvgart Hytrulo.
HALO’s revenues from royalties rose 46.7% year over year to $373.8 million during the first half of 2026.
Halozyme has two commercial proprietary products, Hylenex and Xyosted. Incremental sales from these products also boosted Halozyme’s revenues during the first half of 2026. Total product sales increased 63% year over year to $260.1 million during this period.
Reflecting the strong business performance, Halozyme raised its full-year 2026 financial outlook. The company now expects 2026 revenues of $1.84-$1.91 billion, up from its previous guidance of $1.71-$1.81 billion.
Meanwhile, royalty revenues are now anticipated in the range of $1.22-$1.25 billion compared with the earlier projection of $1.13-$1.17 billion.
Halozyme’s recent business developments and continued growth in royalty revenues from partners are expected to support top-line growth and strengthen its long-term growth outlook. These catalysts could provide further support to the stock’s positive momentum.
Halozyme Therapeutics, Inc. Price
Halozyme Therapeutics, Inc. price | Halozyme Therapeutics, Inc. Quote
HALO's Zacks Rank & Another Key Pick
Halozyme currently carries a Zacks Rank #2 (Buy).
A top-ranked stock in the biotech sector is Repligen (RGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 10% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.